Synolo Therapeutics

Synolo’s antibody-based modular designs achieve conditional disease-specific selectivity across autoimmune diseases and oncology.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
NewCo
Initial Investment Year
2023
Synolo Hover Image